EU Medical Device Regulation Update Demands Rapid Substance Compliance
Event summary
- The EU is updating its Medical Device Regulation (EU MDR) to include 40 new Carcinogens, Mutagens, and/or Reproductive Toxicants (CMRs) and 10 new allergens by 2028.
- The updates stem from Adaptation to Technical Progress (ATP) of the CLP regulation, with 11 new CMRs under ATP 23 and 29 under ATP 24.
- Standard EU MDR sensitization tests are ineffective for detecting the newly classified allergens.
- Claigan Environmental is hosting two webinars on April 8, 2026, to address these changes.
- Compliance requires adjustments to device labelling, instructions for use, and technical files.
The big picture
The EU MDR's ongoing updates, driven by the CLP regulation's ATP, represent a significant shift towards stricter chemical safety standards in the medical device sector. This necessitates a proactive and resource-intensive approach to compliance, potentially impacting smaller manufacturers and increasing the competitive advantage of those with robust due diligence processes. The need for specialized testing and consulting services highlights a growing market opportunity for providers like Claigan.
What we're watching
- Regulatory Headwinds
- The accelerated pace of EU regulatory updates, particularly concerning chemical classifications, will likely increase compliance costs and operational complexity for medical device manufacturers.
- Testing Bottlenecks
- The lack of validated testing methods for the new allergens suggests potential bottlenecks in compliance assessments and could delay product registrations.
- Service Demand
- Demand for specialized compliance consulting and testing services, like those offered by Claigan, will likely remain high as device manufacturers scramble to meet the 2028 deadline.
Related topics